Mandate

VINGE ADVISES PANDOX IN RELATION TO ITS LISTING ON NASDAQ STOCKHOLM

June 18, 2015

Vinge advises Pandox Aktiebolag (publ) in relation to its listing on Nasdaq Stockholm. A prospectus was published on 8 June 2015 and the first day of trading on Nasdaq Stockholm was 18 June 2015. The price in the offering was set at SEK 106 per share, corresponding to a market value of all shares issued by Pandox of SEK 15,900 million. The total value of the offering amounts to SEK 6,360 million, assuming that the over-allotment option is exercised in full.

Pandox is a leading owner of hotel properties located in Northern Europe with focus on sizeable hotels in key leisure and corporate destinations. Pandox’s hotel property portfolio comprises 104 hotels in the upper medium- and upscale segment with a total of 21,969 hotel rooms across eight countries. The market value of Pandox’s property portfolio amounted to SEK 27 billion as of 31 March 2015.

Vinge’s team consisted mainly of Jesper Schönbeck, Charlotte Levin, Erik Sjöman, David Andersson, Joakim Hagberg, Adam Sandberg and Ludvig Berke. Marie Brommesson assisted in due diligence, including financing and property related matters, and Maria Schultzberg and Tora Hansjons assisted in tax related matters.

Related

Vinge advises Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of Bizware

Vinge has advised the Nordic private equity firm Intera Partners’ portfolio company Yellow Elk in connection with its acquisition of the data analytics and AI firm Bizware AB and its subsidiaries Bizware Lead AB and Bizware Nova AB.
September 11, 2025

Vinge has acted as local counsel supporting lead counsel Latham & Watkins in advising Cadence in connection with its acquisition of Hexagon’s Design & Engineering Business for approx. EUR 2.7 billion

Cadence (Nasdaq: CDNS) announced it has entered into a definitive agreement to acquire the Design & Engineering business of Hexagon AB, which includes its MSC Software business—a pioneer in engineering simulation and analysis solutions.
September 09, 2025

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025